In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities

This article was originally published in The Gray Sheet

Executive Summary

A settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.

You may also be interested in...

Boston Scientific Expects PMA Supplement To Further Delay SOX Re-Launch

Boston Scientific likely will submit data to FDA in the form of a premarket approval application supplement for the relaunch of the Nir-On-Ranger with SOX securement system, leading analysts to envisage a second-half 1999 return to market for the pre-mounted coronary stent system.

Boston Scientific To Report Q3 Results By Nov. 14 Despite Japan Difficulties

The detection of $40-50 mil. in improperly recorded sales in 1998 by Boston Scientific's Japan subsidiary is bittersweet testimony to the effectiveness of the firm's recently installed corporate SAP computer system.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts